Fig. 3
![Fig. 3](http://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs40425-018-0424-9/MediaObjects/40425_2018_424_Fig3_HTML.png)
a PFS and b OS in the overall population (N = 50), and c PFS and d OS based on PD-L1 expression on tumor cells (5% cutoff) in evaluable patients (n = 42). NE, not evaluable
a PFS and b OS in the overall population (N = 50), and c PFS and d OS based on PD-L1 expression on tumor cells (5% cutoff) in evaluable patients (n = 42). NE, not evaluable